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MicroRNAs are gaining importance as regulators of gene expression with the capability to ﬁne-tune and modulate cellular events.
The complex network with their selective targets (mRNAs/genes) pave way for regulation of many physiological processes. Dys-
regulation of normal neuronal activities could result in accumulation of substances that are detrimental to neuronal functions and
subsequentlyresult in neurotoxicity. Neurotoxicity-mediated pathophysiological conditions could then manifest as diseases or dis-
abilities like Parkinson’s and Alzheimer’s which have debilitating implications. Such toxicity can be a result of individuals predis-
posed due to genetic inheritance or from other sources such as brain tumours. Neurotoxicity can also be brought about by exter-
nalagents likedrugsand alcohol as well as braininjurywith miRNAsplaying apivotal rolein diseases. Itisthereforevital to under-
stand the expression of these microRNAs and their impact on neuronal activities. In this paper, we discuss some of the neuronal
pathophysiological conditions that could be caused by dysregulated microRNAs.
1.Introduction
MicroRNAs (miRNAs) are fast emerging as important regul-
ators of gene expression, controlling almost every activity of
a cell from development to cell death [1–6]. These riboregu-
lators were ﬁrst discovered in Caenorhabditis elegans in 1993
[7] after which numerous reports on the miRNA-mRNA re-
lationships and the resulting functional regulations have
been documented [6, 8–14].
MicroRNAs (miRNAs) are endogenous, small (∼23nt),
noncoding RNAs that are capable of regulating translation
and transcription of speciﬁc mRNAs and gene promoters [7,
15–19]. A single miRNA is also capable of regulating a my-
riad of genes [20]. These miRNAs are derived from long
stem-loop transcripts by the action of nucleases Drosha and
Dicer (RNaseIII enzyme). The mature miRNA forms a com-
plex with the RNA-induced silencing complex (RISC) and
subsequently interacts with its targets to bring about RNA
interference (inhibition or activation) [21].
Tissue-speciﬁc and organ-speciﬁc miRNAs have also
been elucidated [22]. MiRNAs are abundant in the central
nervous system. MiRNAs that are speciﬁcally expressed and
enriched in the brain are implicated in maintaining normal
neuronal function and homeostasis which in turn is associ-
atedwithmemory,neuronaldiﬀerentiation,synapticplastic-
ity, and neurogenesis as well as neuronal degeneration [23–
26]. The brain-speciﬁc miR-9 targets the stathmin mRNA
and has been implicated in early neurogenesis and prolifera-
tion while decreasing migration of young neural progenitor
cells [27]. Another brain-speciﬁc miRNA, miR-124 has been
implicated in neuronal diﬀerentiation. MiR-124 directly
targets the polypyrimidine tract-binding protein 1 (PTBP1),
which encodes a global repressor of alternative pre-mRNA
splicing in nonneuronal cells. MiR-124 mediated reduction
in PTBP1 levels, increases the correctly spliced PTBP2 pro-
tein which promotes nonnervous system to nervous system-
speciﬁc alternative splicing patterns. Hence, miR-124 pro-
motes nervous system development as well as plays a key role
in the diﬀerentiation of progenitor cells to mature neurons
[28]. The brain-speciﬁc miRNAs could individually or col-
lectively promote and maintain neuronal development [29].
Numerous other miRNAs have also been reported in brain
functionincludingmiR-134whichmodulatesspineandden-
drite development [4].
Neuronsusuallyrequireatightcontrolinseveralgeneex-
pression pathways. Dysregulation in any one of these could2 Journal of Toxicology
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have drastic eﬀects on the expression of downstream genes
and proteins that could eventually oﬀset the balance and
function of the neurons. Abnormal expression and protein
function could give rise to the inability of the neuron to clear
waste products. Accumulation of waste products could result
in toxicity, cell death, or malfunction of the neurons.
Neurotoxicityisaresultoftheadverseeﬀectsofchemical,
biological, and certain physical agents on the nervous system
and/or behavior during development and in maturity. These
agents could be either endogenously produced by the ner-
vous system or could be acquired from exogenous sources.
Both the central and peripheral nervous system are very sen-
sitive, such that any minor change in the structure or fun-
ction of the nervous system might have profound conseq-
uences on neurological, behavioural, and related body fun-
ctions [9]. This applies to miRNA levels as well. The cells of
central nervous system (CNS) comprise neurons and glial
cells (astrocytes, oligodendrocytes) while the peripheral ner-
vous system system has mainly Schwann cells [30].
Ablation of miRNA processing enzyme, Dicer has been
found to result in cell death, and ataxia in postmitotic Pur-
kinge cells [31]. Similarly, Tao et al. [32] reported that Dicer
is essential for maturation and maintenance of cerebellar
astrocytes. Dysfunctional dicer has been found to result in
neurological disorders like ataxia, seizures, severe progressive
cerebellar degeneration and premature death [32]. These
events could also lead to the spread of neurotoxicity to the
surrounding neurons which depend on neurotransmitters
like glutamate and acetylcholine [33].
MiRNAs are therefore of utmost importance in main-
taining neuronal homeostasis and their dysregulation could
result in neurotoxicity. This review will focus on miRNAs
that have been demonstrated to contribute to diﬀerent types
of neurotoxicity (Figure 1).
2.DysregulationofCellularActivitesThat
LeadtoNeurotoxicity
Malfunction of the cellular machinery could lead to altera-
tion of miRNA expression which would result in aberrant
expression of target mRNAs. This dysregulation could alter
several downstream pathways and manifest eﬀects like deﬁ-
ciency in clearance of cellular by-products. These alterations
in miRNA expression and subsequent accumulation of neu-
ron speciﬁc by-products are responsible for age-dependent
neurodegeneration [5].
2.1. Dysregulation of NMDA Receptor Function. N-Methyl-
D-aspartate (NMDA) receptors are responsible for neuro-
transmission as well as neuronal plasticity [34]. Dysregula-
tion of gene expression in this pathway has been shown to
giverisetodisorderslikeschizophrenia[35],bipolardisorder
[36] and autism [37, 38]. Disruption of NMDA-mediated
glutamatesignalinghasalsobeenlinkedtobehavioraldeﬁcits
displayed in psychiatric disorders such as schizophrenia.
Kocerh et al. [39] showed that pharmacological (dizocilpine
administration) or genetic (NR1 hypomorphism) disruption
of NMDA receptor signaling reduced the levels of a brain-
speciﬁc miRNA, miR-219, in the prefrontal cortex (PFC) of
schizophrenic mice models. MiR-219 has been shown to
negatively regulate a vital molecule, Ca2+/calmodulin-depen-
dent kinase II γ (CaMKIIγ), in the NMDA receptor signalling
cascade. The downregulation of CaMKIIγ in the prefrontal
cortex results in loss of synaptic plasticity [39]. Dizocilpine,
an NMDA receptor antagonist, was shown to simulate this
downregulation which could be reversed by pretreatment
with antipsychotic drugs like clozapine and haloperidol, thus
facilitating NMDA receptor function [39]. Mellios et al. [40]
observed that miR-195 is downregulated in postmortemJournal of Toxicology 3
brain of schizophrenia patients. The authors reported that
miR-195targetsbrainderivedneurotrophicfactor (BDNF)ex-
pression and indirectly reduces the expression of GABAergic
genes, neuropeptide Y (NPY)a n dsomatostatin (SST). It is
noteworthy that disruption of NMDA-mediated glutamate
signaling resulting from dysregulated GABAergic gene ex-
pression, has been widely reported in the prefrontal cortex of
subjects with schizophrenia [40]. MiR-195 has also been
speculated to be the main regulator of the schizophrenia net-
work in partnership with early growth response 3 (EGR3)
[41]. Moreover, Beveridge et al. [42] showed signiﬁcant up-
regulation of miR-181b in the temporal cortex of postmor-
tem Schizophrenia patients and downregulation of their res-
pective targets such as calcium sensor gene visinin-like 1
(VSNL1)andtheionotropicAMPAglutamatereceptorsubunit
(GRIA2)[ 42].
2.2. Neurotoxicity as a Result of Aggregation or Accumulation
of Toxic Proteins. Aggregation and accumulation of toxic
levels of undesirable proteins either due to overexpression or
incorrect processing results in death of a targeted group of
neurons which manifests symptoms that depict a loss of fun-
ction of those cells. Such defects result in debilitating neuro-
logical diseases like in Parkinson’s disease (PD), where α-
synuclein accumulates in dopaminergic neurons. In the Al-
zheimer’s disease (AD) condition, inappropriate enzymatic
activity results in accumulation of Aβ amyloid protein ag-
gregates.
2.2.1. α-Synuclein Accumulation and Parkinson’s Disease.
Five genes, α-synuclein, parkin, dj-1, pink1,a n dlrrk2,h a v e
been implicated to play a role in the pathogenesis of PD [43,
44]. Signiﬁcantly increased levels of α-synuclein are detri-
mental to dopaminergic neurons [45]a n dﬁ b r i l l a rα-syn-
uclein accumulation in Lewy bodies and Lewy neurites have
been reported in postmortem samples [46].Theseaggregates
display impaired function of chronic loss of dopaminergic
neurons in the substantia nigra pars compacta in patients
who manifest disabling motor abnormalities accompanied
by dementia and hallucinations [45].
Studies on the role of miRNAs in PD started with dele-
tion of Dicer indopamine neurons.AbsenceofDicer resulted
in progressive loss of dopamine neurons as well as expression
of Parkinson’s-like behaviors [47] and reduced neuronal size
andastrogliosisindopamine-receptiveneuronslackingDicer
[48]. MiR-7, expressed mainly in the neurons, has been
shown to protect the cells against oxidative stress by repress-
ing α-synuclein translation. In both cultured cells and mice
model of PD, administration of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) resulted in decreased expression
of miR-7 and increased α-synuclein expression [45]. Similar-
ly, Doxakis [49] found that both miR-7 and miR-153, which
are predominantly expressed in the brain, could repress
α-synuclein expression and regulate it posttranscriptionally
[49]. Midbrain dopaminergic neurons speciﬁc miRNA, miR-
133b was found to control the maturation of the dopaminer-
gic neurons by suppressing the homeodomain transcription
factor, Pitx3.K i me ta l .[ 47] reported that Pitx3,w h i c h
was signiﬁcantly downregulated in PD brains, was not only
a direct target of miR-133b but it could also regulate trans-
cription of miR-133b through a sensitive negative feedback
loop [47].
Another group, Asikainen et al. [50] went a step further
to focus on other genes as well. Analysis of expression of
miRNAs in PD-associated C. elegans models showed under-
expression of the family of miR-64 and miR-65 in human
A53T α-synuclein overexpression and mutated vesicular
catecholamine transporter (cat-1) model animals, as well as
underexpression of let-7 family members in the α-synuclein
overexpression and parkin (pdr-1) mutated strains. MiR-64
and miR-65 potentially target mdl-1 and ptc-1 genes which
were highly expressed in the model animals compared to
healthy ones as well as in miR-64/miR-65 knockout animals
[50]. However, there is a need to validate these results in
rodent experiments as well as postmortem human brain
samples.
2.2.2. Aβ Aggregation and Alzheimer’s Disease. Alzheimer’s
Disease (AD) is characterized by clinical manifestations of
progressive loss of memory and other cognitive functions.
Earlysynaptic loss contributetodisease progression[51]and
subsequent neuronal loss leads to generalized brain atrophy.
Formation of neuroﬁbrillary tangles (NFTs) that comprise
the microtubule associated protein, tau, and neuritic plaques
composedofamyloid-β (Aβ)arethecauseofpathogenesisin
AD [52, 53]. Aβ (predominantly 40 amino acid polypeptide,
Aβ40) is a naturally occurring protein. It is cleaved from the
larger amyloid precursor protein (APP) by the synapse for-
mationregulatorenzyme,α-secretase[52].However,proteo-
lytic cleavage by β-secretase (BACE-1 or β-site APP-cleaving
enzyme) and γ-secretase results in the formation of another
longer form, Aβ42, which forms higher-order aggregates
which subsequently result in plaque deposition (Figure 2).
Although it is well-established that Aβ42 accumulation gives
rise to AD pathology, the mechanism and signalling cascades
that give rise to its toxicity have yet to be elucidated [54].
Nevertheless,inﬂammation,mitochondrialdysfunction,oxi-
dative stress, and calcium dysregulation have been proposed
to contribute to the toxicity [55].
Proﬁling of postmortem human AD brain samples has
veriﬁed that signiﬁcant changes in miRNA expression occur
in several brain regions [56]. The miRNAs studied included
miR-20a family and miR-107 which regulate APP and
BACE1, respectively [57–59]. Schonrock et al. [53]ﬁ r s te x -
amined how Aβ itself causes neuronal miRNA deregulation
thatcontributetothepathologicalmechanisms ofAD.Treat-
ment of primary cultures with Aβ peptides downregulated
almost50%oftheanalysedmiRNAs.Similarresultswerealso
demonstrated at the onset of Aβ plaque formation in the
Aβ42-depositing APP23 mice. These results showed the
downregulation of miR-9, miR-181c, miR-30c, miR-20b,
miR-148b, and let-7i as observed in human AD studies [58].
The downregulated miRNAs miR-9, miR-30, and miR-20
werealsopredictedtoaﬀecttargetgenesthatwereimplicated
in axonal guidance. Therefore, neuronal miRNA deregula-
tion and consequently, gene dysregulation at the early stages4 Journal of Toxicology
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duetoAβ maybeanimportantfactorcontributingtodisease
progression and toxicity of AD [53]. Nunez-Iglesias et al.
[60] also found that miR-148b, miR-20b, and miR-181c were
downregulated among the 48 signiﬁcantly deregulated miR-
NAs in the parietal lobe cortex of AD patients.
In AD brain cortical and cortical white matter samples
a reduced expression of miR-101 has also been observed
[58, 60]. MiR-101 negatively regulates APP and hence is con-
sidered to have a potential of being developed as a therapeu-
tic target to attenuate Aβ42 accumulation and downstream
pathogenic mechanisms underlying AD [61]. Moreover,
miR-20a, miR-17-5p, and miR-106b (miR-20a family), miR-
106a, miR-520c, and miR-16 have also been shown to regu-
late APP expression [59, 62, 63]. Smith et al. [64] found that
miRNAs regulate neuronal splicing of APP in vivo. MiR-124
was considered to serve as an indirect regulator of APP splic-
ing [64].
Apart from APP, the enzyme responsible for inappro-
priate cleavage of APP, BACE1 has also been studied for var-
iationsthatmightgiverisetotheADdisease.MiRNAexpres-
sion studies on human brain tissue showed signiﬁcantly
reduced miR-107 levels in patients in the early stages of the
disease [57]. This miRNA was validated to target the 3 UTR
of BACE1andhence,couldhaveacrucialroletoplayinacce-
lerated disease progression through regulation of BACE1.
MiRNA proﬁling showed that the miR-29a/b-1 cluster was
signiﬁcantly decreased in AD patients presenting abnormally
high BACE1 protein and miR-29a, miR-29b-1, and miR-9
were observed to negatively regulate BACE1 expression in
primarycellculture.LossofspeciﬁcmiRNAslikethemiRNA
clustermiR-29a/b-1insporadicADwasthereforeconsidered
to contribute to increased BACE1 and subsequently Aβ levels
[58].
The development and progression of AD is due to ele-
vated inﬂammatory signals triggered by overactivation of
NFκB. This transcription factor speciﬁcally upregulated
miR-146a in the AD brain, and negatively regulated an im-
portant repressor of the brain inﬂammatory response, com-
plement factor H (CFH)[ 65]. This correlated with downreg-
ulation of CFH as well as interleukin-1β and Aβ42 in oxida-
tively stressed human neural (HN) primary culture cells.
Hence, NF-κB sensitive miRNA-146a-mediated modulationJournal of Toxicology 5
of CFH gene expression could also regulate an inﬂammatory
response in AD brain. MiRNA-146a has also been shown to
be an NF-κB-sensitive endotoxin-responsive gene, and pre-
dicted to target tumor necrosis factor receptor-associated factor
6 and IL-1 receptor-associated kinase 1 mRNAs [66, 67].
ElevatedexpressionofmiRNA-146acorrelatedwithsenile
plaque density and synaptic pathology as well as pathophys-
iological stress factors in vivo and in vitro as well as in AD
postmortem brain samples [68]. Elevated levels of the
BACE1-antisensetranscriptalongsidedysregulatedmiR-485-
5p levels in AD patients implicating increased stability of the
BACE1 transcript by preventing interaction between miR-
485-5p and its seed sequence [69].
These studies conﬁrm that the accumulation of APP and
subsequent Aβ by-products lead to neurotoxicity that man-
ifests as Alzheimer’s disease. This is probably mediated by a
network of miRNAs, in particular miR-9, miR-30 and miR-
20, miR-29a/b-1 cluster, miR-146a, miR-124, and miR-485-
5p. These miRNAs have been demonstrated to either target
the APP splicing/expression or the production of Aβ.
3.GeneticallyTransferred(Inherited)
CauseofNeurotoxicity
Genetic inheritance of genes implicated in toxicity or poly-
morphisms are also risk factors of neurotoxicity and could
have dire consequences as compared to sporadic onset. Gen-
eticmultiplicationoftheimplicatedgeneslikeα-synucleinin
PD results in early onset and increasing severity of dementia
in a gene dosage-dependent manner [70, 71].
Single nucleotide polymorphism genotyping identiﬁed
ﬁbroblast growth factor 20 (FGF20) at chromosome 8p21.3–
22 as a risk factor for PD [72]. The strongest association was
observed between single-nucleotide polymorphism at
rs12720208inthe3 UTRofFGF20.Theriskallelewasshown
to disrupt (mutate) the binding site for miR-433, increasing
translation of FGF20 that was accompanied by an increase in
α-synuclein expression, in both in vitro and in vivo studies.
Hence, single-nucleotide polymorphism of the FGF20 gene
resulted in chronic elevation of α-synuclein levels in human
brain that translated to increased susceptibility to PD. It is
noteworthy that early in life, FGF20 is beneﬁcial to prolifer-
ation, diﬀerentiation, and even neuroprotection of the mid-
brain dopaminergic neurons. However, at later stages of de-
velopment, the signiﬁcantly elevated levels of FGF20 could
indirectly contribute to neurotoxicity that results in dopa-
minergic neuron death. This risk allele is thus an important
component to determine individual susceptibility to this
debilitating disease and has opened the way for the potential
use of miR-433 and FGF20 as therapeutic and diagnostic
markers [72].
Huntingtondisease(HD)islargelyahereditaryneurode-
generative disorder associated with expansion of the polyg-
lutamine region in the gene encoding the protein huntingtin
(Htt). Neurodegeneration results in defects in cognition and
motor control, leading to chronic loss of cortical and striatal
neurons and death. The mutant Htt confers toxicity to the
neurons and eliminates the neuroprotective eﬀects of the
wild-type Htt [73]. In normal neurons, transcriptional re-
pressor, REST (repressor element 1 silencing transcription
factor) regulates the expression of Htt [74]. Mutant Htt
showed reduced expression of proteins that were vital for
neuronal survival and function, conferring neurotoxicity.
Johnson and Buckley [75] examined the abnormal expres-
sion of neuron-speciﬁc miRNAs in the tissues from HD pa-
tients and observed signiﬁcant downregulation of miR-132.
MiR-132 was shown to target REST, that was required for
neurite growth and could therefore, account for the loss of
signal transduction of the diseased neurons [76–78]. MiR-
34b was observed to be stable in plasma and signiﬁcantly ele-
vated in HD gene-carriers even before the symptoms were
presented [79]. Signiﬁcant downregulation of numerous
miRNAswasobservedincorticesofHDpatients,inclusiveof
the bifunctional brain enriched miR-9 and miR-9∗ which
targeted REST and CoREST, making up the REST silencing
complex [80].
MiRNAs implicated in neurotoxicity in diseases of CNS
and their related functions are listed in Table 1.
4. BrainTumour(s) InducedNeurotoxicity
Dysregulation of gene expression within the neurons could
also result in uncontrolled cell growth leading to formation
oftumours.Braintumoursarecategorizedasglioblastomain
adults and medulloblastoma in children. Glioblastoma is the
most common and most lethal brain tumour. MiR-221 and
miR-222 are overexpressed in human glioblastoma. These
miRNAs have been validated to negatively regulate the pro-
teintyrosinephosphataseμ(PTPμ)genethathasbeenobserv-
ed to be downregulated in these tumour cells [96]. The spe-
culated inverse relationship was observed in vitro as well as
in glioma cancer patient samples.
Inhibition of miR-10b decreased growth of the tumour
by retraction from the cell cycle and encouraging program-
medcelldeath[97].Thiswasfacilitatedbyexpressingthetar-
gets of miR-10b—BCL2L11/Bim, TFAP2C/AP-2γ, CDKN1A/
p21,a n dCDKN2A/p16 that regulated controlled cell growth.
MiR-10b was therefore responsible for uncontrolled cellular
growth by downregulating proapoptotic genes. Decreased
survival of glioblastoma patients with high miR-10b expres-
sion was observed, implicating its in vivo f u n c t i o n sa sw e l l .
Successful treatment was also reported to suggest its thera-
peutic potential [97].
MiRNA-146a was shown to be upregulated in epidermal
growth factor receptor (EGFR) dysregulated cells in gliomas.
MiR-146a targets Notch1 which maintains neural stem cells,
thus controlling proliferation and diﬀerentiation of neural
stemcells.Ingliomas,upregulationofmiR-146awaspropos-
ed to counter tumourigenicity, in a negative feedback-loop
fashion [98]. MiR-21, an antiapoptotic miRNA has been
widelyimplicatedincancer.Itwasfoundtobeupregulatedin
medulloblastoma and inversely correlated to the metastasis
suppressor PDCD4. PDCD4 positively regulated E-cadherin
and tissue inhibitor of metalloproteinase-2 (TIMP2), the
negative modulators of cancer cell migration, thus resulting
in an increased cell motility and migration [99]. LRRC4 is6 Journal of Toxicology
Table 1: MicroRNAs involved in diseases due to dysregulation of normal cellular activites.
Description Upregulated
(miRNA)
Downregulated
(miRNA) Function/target
Dysregulation of NMDA receptor function
Schizophrenia miR-219 Targets CamKIIγ to result in NMDA receptor
hypofunction [39]
miR-181b Other dys–
regulated miRNAs:
miR-199a, miR-128a,
and miR-128b [81–
83]
V S N L 1a n dG R I A 2[ 42]
Aggregation and accumulation of toxic proteins
α-synuclein in dopaminergic
neurons: Parkinson’s disease
miR-7 [45] α-synuclein
miR-153 [49] α-synuclein
miR-133b [47]P i t x 3
miR-64 and miR-65
[50] mdl-1 and ptc-1
Aβ aggregation in basal
forebrain, hippocampus, and
association cortices: Alzheimer’s
disease
miR-101 APP [84]
miR-107 BACE1 [57]
miR-29a/b-1 BACE1 [58]
miR-146a Targets CFH to elicit inﬂammatory response [85]
miR-485-5p Stability of BACE1-antisense prevents repression of
BACE1 by blocking this binding site [69]
Inherited disorders
Parkinson’s disease Risk allele disrupts binding site of miR-433 in 3 UTR
of FGF20 [72]
Huntington’s disease miR-132 [76–78]
miR-9 and miR-9∗ Target REST and CoREST which repress genes vital to
neuronal survival and function [80]
Tourette’s syndrome Mutation in miR-189
binding site SLITRK1 [86]
Williams syndrome miR-134 LimK1 [24]
Rett syndrome miR-132 MeCP2 [87, 88]
Fragile X mental retardation miR-125b NR2A [89]
Others
Amyotrophic lateral sclerosis
(ALS) miR-206 Derepresses histone deacetylase 4, an inhibitor of
muscle reinnervation [90]
Spinal motor neuron disease miR-9
Targets NEFH, heavy neuroﬁlament subunit of upper
and lower motor neurons, leading to paralysis and
death [87]
Spinocerebellar ataxia 1 (SCA1) miR-19, miR-101, ATXN1 [84]
miR-130
Spinal cerebellar ataxia type 3
(SCA3) Bantam Ataxin-3 toxicity, polyglutamine- and tau-induced
neurodegeneration [91]
Dentatorubral-pallidoluysian
atrophy (DRPLA) miR-8 Atrophin-1 [92]
Frontotemporal dementia miR-29b Downregulation of the secreted glycoprotein, human
progranulin [93]
Aicardi-Gouti` eres syndrome Silencing of RNAse activity leading to miRNA
overload [94]
Ageing (ad libitum versus to
calorie-restricted diet)
miR-181a-1∗,
miR-30e and miR-34a
in ad libitum mice as
compared to CR regi-
men
Target Bcl-2 to increase proapoptosome speciﬁc
proteins and thus rate of neuronal apoptosis [95]Journal of Toxicology 7
aglioblastomasuppressorgenespeciﬁctothebrainandatar-
get of miR-381. Repression of LRRC4 by miR-381 promoted
glioma cell proliferation. At the same time, LRRC4 has also
been found to inhibit the expression of miR-381 in the cell
and decrease cell proliferation and tumour growth [100]. In
addition, a recent study by Srinivasan et al. [101] identiﬁed
ten miRNAs that correlated to the survival of glioblastoma
patients. Three miRNAs, miR-20a, miR-106a, and miR-17-
5p, were protective in nature and seven miRNAs, miR-31,
miR-222, miR-148a, miR-221, miR-146b, miR-200b, and
miR-193a, were categorized as risk markers in terms of pa-
tient survival. Protective miRNAs (decreasing tumorigenic-
ity) were more abundant in the low risk group while the
miRNAs that increased tumorigenicity (risk indicators) were
more abundant in the high-risk group [101]. Such informa-
tion is thus vital in prognosis of the disease.
5. Exogenous FactorsContributing
toNeurotoxicity
5.1. Alcohol. Long-term ethanol abuse could lead to ethanol-
induced neurotoxicity which changes the expression of genes
implicated in myelination, ubiquitination, apoptosis, cell ad-
hesion, neurogenesis, and neural disease [102]. Gene expres-
sion proﬁling of postmortem brain of long-term alcohol
abusers allowed determination of the eﬀects of alcohol in the
brain [102–107]. Examination of dysregulated miRNAs in
the samples of alcoholic and nonalcoholic age- and sex-mat-
ched controls showed that expression of approximately 35
miRNAs was signiﬁcantly upregulated in the alcoholic group
[108]. Target prediction analysis showed an inverse relation-
ship between the upregulated miRNAs and the targeted
mRNA in human alcoholic cases. These mRNAs and their
genes were implicated to downregulate the pathways involv-
ed in the central nervous system development and synapse
formation [109].
Peripheral myelin protein 22 (PMP22)is regulatedbylong
termethanoluseandatargetofmiR-29athussuggestingthat
miRNAs could regulate myelin gene expression [102, 104,
106, 110]. Moreover, miRNAs altered in neurodegenerative
diseases like Alzheimer’s, Parkinson’s, and prion diseases
have also been shown to be signiﬁcantly dysregulated in the
prefrontal cortex of alcoholics [45, 59, 102, 111].
Pietryzkowski et al. [112] showed that the large-conduc-
tance calcium-and voltage-activated potassium channel (BK)
was a target for miR-9 and exposure to alcohol upregulates
miR-9 and mediated posttranscriptional reorganization in
BK mRNA splice variants. In a study to demonstrate how the
neurons adapt or confer protection during acohol exposure,
the authors showed that an increase of miR-9 correlated to
altered expression of alpha subunit of BK channel isoforms
[112]. Notably, the BK channel isoforms, confered varied
sensitivitytoethanolexposure.Someisoformswereverysen-
sitive while others had low sensitivity or even innate toler-
ance to ethanol. Pietryzkowski et al. [112] showed that
3 UTR of BK isoforms of high ethanol sensitivity had a miR-
9 binding site that was absent in the ethanol-tolerant BK iso-
forms. Thus, the expression of the ethanol insensitive BK
isoformswasnotaﬀectedbyethanol.Hence,tiltingthehom-
eostasis of BK isoforms towards the ethanol-tolerant iso-
forms in the brain to maintain the expression of BK for neu-
ronal plasticity and function [102, 105–107, 113, 114].
Experiments using cell culture models of the second tri-
mester fetal neuroepithelium showed that fetal stem cells
(NSCs)/progenitorcells(NPCs)wereadirecttargetofethan-
ol [115]. It has been hypothesized that ethanol promotes cell
cycle, resulting in increased maturation, and consequently,
depletion of stem and early progenitor cells [115, 116]. Addi-
tionally, diﬀerentiating neuroblasts, derived from ethanol
preexposed neurosphere cultures exhibited signiﬁcantly in-
creased migration, compared to nonexposed controls [117]
which supported continual organizational eﬀects of ethanol
in NSCs/NPCs [116]. Four miRNAs, miR-9, miR-21, miR-
153, and miR-335 had been shown to be suppressed by
ethanol in NSCs/NPCs [118]. Ethanol mediated simultan-
eoussuppressionofmiR-21,miR-153,andmiR-335account-
ed for the resistance of ethanol-exposed NSCs/NPCs to apo-
ptosis. MiR-335 suppression was suggested to be the cause of
ethanol-induced cell proliferation in neurosphere cultures
[116]. Notch receptor ligand, Jagged-1, and neuron-speciﬁc
RNA binding protein ELAVL2/HuB were both predicted tar-
gets of at least three of the four suppressed miRNAs, with
miRNAs-335, -21, and -153 targeting Jagged-1 and miRNAs-
335, -153, and -9 targeting ELAVL2, and the expression of
both genes was thereby induced by ethanol in neurosphere
cultures [118]. ELAVL2/HuB overexpression promoted neu-
ronal diﬀerentiation [119]a n dJagged-1-induced prolifera-
tionestablishedneuronalidentity[120].Boththeseprocesses
of proliferation and diﬀerentiation being triggered simulta-
neously by ethanol would account for promotion of NSC
maturationandcellcycleinductionwithoutcelldeathviade-
repression of miRNA-inhibited neuronal identity factors
[118].Theupsetofthebalancebetweencellsurvivalandpro-
liferation depletes stem cells contributing to dysregulation of
normal function, and thus neurotoxicity in the growing
fetus. Hence, excessive ethanol consumption during preg-
nancy could lead to growth retardation, mental retardation,
and a mix of craniofacial, cardiovascular and skeletal defects
collectively termed the “fetal alcohol syndrome” or FAS
[121]. MiRNA expression was sensitive to ethanol especially
during development and could mediate ethanol teratology
[118, 122]. Prenatal ethanol exposure resulted in upregula-
tionofmiR-10aanddownregulatedHoxa1expressioninfetal
brains [122]. In cultured embryos, dysregulation of Hoxa1
gene lead to birth defects especially in the brain [122]. The
group also established that folic acid could rescue this ethan-
ol-induced teratogenesis by downregulation of miR-10a ex-
pression [122].
5.2. Nicotine. There is a high correlation between alcohol
consumption and tobacco use. Both preclinical and clinical
data provide evidence that nicotine administration increases
alcohol intake and nonspeciﬁc nicotinic receptor antagonists
reduce alcohol-mediated behaviors [123].
Nicotine-mediated neurotoxicity is well established and
chronic use of nicotine confers addiction and altered neu-
ronal functions. Huang and Li [124] tested the eﬀects of8 Journal of Toxicology
nicotineonneuronalcultures.Theyreportedthatshort-term
nicotine exposure upregulated the expression of 11 miRNAs
(miR-188, miR-137, miR-328, miR-181b, miR-503, miR-
140∗, miR-351, miR-125b, miR-93, miR-26a, and miR-25),
while downregulating the expression of an additional 14
miRNAs (miR-301a, miR-10b, miR-30a-5p, miR-186, miR-
29c, miR-101a, miR-152, miR-21, miR-30c, miR-374, miR-
335, miR-210, miR-98, and miR-352). MiR-140∗ was upreg-
ulated in nicotine exposure and targeted several genes impli-
catedinneuronalfunction,includingDnm1whichencodesa
large GTPase, dynamin-1, required for synaptic endocytosis
[124, 125]. Therefore, nicotine-induced neural activities
could be modulated by miR-140∗. Furthermore, morphine-
administered rats also revealed an enriched postsynaptic lo-
calization of dynamin 1 in the hippocampus [126], demon-
strating a potential role of dynamin 1 and miR-140∗ in drug-
induced neural plasticity and subsequent neurotoxicity.
5.3.Morphine. Opioiddrugs,suchasmorphine,areaclassof
powerful analgesics that are used for treating many forms of
acute and chronic pain. Their chronic use results in undesir-
able eﬀects such as drug tolerance, opioid-induced pain, and
opioid dependence as well as reducing the size of the
dopaminergic neurons [127, 128]. This analgesics also
forms a common drug of abuse that could have dire con-
sequences for the neurons upon repeated intake. Mor-
phine functions via the μ opioid receptor to bring about
changes in miRNA expression in neurons. Morphine regu-
latedthemiR-133b:Pitx3pairtoincreasePitx3expression in
immature hippocampal neurons, thus promoting neurotox-
icity in neuronal diﬀerentiation [129]. Pitx3 was responsible
for activation of the dopaminergic neuron gene expression
and function as discussed in toxicity leading to PD, both of
which share similar gene dysregulation. It is likely that this
samemechanismoftoxicitycouldresultinmorphineabusers
developingsymptomssimilartoPDpatients(Figure 3).Also,
morphine has been shown to elevate let-7 expression which
targets the μ opioid receptor, thereby decreasing protein levels
and sensitivity to the drug, giving rise, to drug tolerance.
5.4.Cocaine. Cocaineisastrongstimulantofthecentralner-
vous system that increases levels of dopamine, and results in
accumulationofthisneurostimulantintheneurons.Cocaine
is another drug of abuse that results in increased craving for
the drug over long period of consumption [127]. Changes in
neuronal networks form the basis of decreased responses to
the same dose of a drug over time [130]. MiR-212 has been
shown to be highly expressed in the striatum of rats. Hol-
lander et al. [131] showed that increased miR-212 expression
correlated with prolonged consumption of cocaine. MiR-212
has been demonstrated to decrease the downstream signall-
ing response of cocaine by increasing sensitivity of adenylyl
cyclase, thereby, magnifying the stimulatory eﬀects of the
drug on cAMP response element binding protein (CREB)
signalling [131]. Im et al. [132] have also attributed miR-212
interaction with the X-linked transcriptional repressor
methylCpGbindingprotein2(MeCP2)todecreaseexpression
of MeCP2 and downstream BDNF which is responsible for
the plasticity induced in striatal neurons resulting in cocaine
addiction[132].Thisisyetanotherexampleofﬁne-tuningin
the central nervous system in response to adverse reactions
like addiction in an attempt to counter it. Cocaine-induced
neurotoxicity thus could be reversed in the presence of miR-
212.
MicroRNAsregulatetheexpressionofdrug-metabolizing
enzymes and transporters. Brain speciﬁc miR-124a was
found to be downregulated by psychoactive drugs like coca-
ine, methadone, and ﬂuoxetine in BE(2)-M17 and SH-SY5Y
cells [133]. MiRNA-18a was also found to be downregulated
in the presence of DMT, 5-MeO-DMT, harmaline, methyl-
phenidate, and methadone (psychoactive drugs). MiR-18a
has been shown to regulate posttranscriptional gene expres-
sion of glucocorticoid receptor (GR/NR3C1)[ 134]a n destro-
gen receptor-alpha (ERa/NR3A1)[ 135, 136] which are ligand
inducible transcription factors controlling development,
metabolism, immune response, and neuronal diﬀerentia-
tion [133]. Interestingly, miR-18a was elevated by desipra-
mine, a tricyclic antidepressant. Prolonged treatment with
desipramine increased miR-18a expression while downreg-
ulating the expression of GR/NR3C1 in Wistar-Kyoto rats
andmanifestedintodepressivebehavior.Identiﬁcationofthe
underlying mechanisms would ultimately provide increased
understanding of the eﬀects of the drugs and cellular defense
against xenobiotic agents. Therefore, psychoactive agents
signiﬁcantly alter the expression of neuronal miRNAs.
5.5. Prion as Biological Neurotoxins. Prion disease or trans-
missible spongiform encephalopathies (TSEs) are the conse-
quence of infection that results in a fatal structural change
of the normal cellular prion protein, PrPC (prion protein
cellular) into PrPSc (prion protein scrapie) [137]. Upregula-
tion of miR-342-3p has been observed in bovine spongiform
encephalopathyinfectedmacaquesand correlated to increas-
ed expression in brain samples of (sporadic) human patients
[111]. Similarly, using mouse model of prion disease, Saba
et al. [138] identiﬁed a group of 15 miRNAs to be dysregul-
ated.BesidesthemiR-342-3p, theexpressionofmiR-320,let-
7b, miR-328, miR-128, miR-139-5p, and miR-146a were also
found to be upregulated and miR-338-3p and miR-337-3p
were downregulated in the prion induced neuronal toxicity
[138]. The authors proposed that the coordinated dysregula-
tion of these miRNAs could be a consequence of abnormal
accumulation of PrPSc that resulted in neurotoxicity. The
process could include compensatory modulation of miRNA
expressions that regulated the neuronal activities as well as
protein degradation and signaling pathways that could have
led to failure in neuronal function.
Otherexogeneousagentscomprisingenvironmentalstre-
ssorsandtoxiccompoundslikehexahydro-1,3,5-trinitro-1,3,
5-triazine (RDX) could also cause dysregulation in miRNA
proﬁle that results in neurotoxicity [139].
6. BrainInjury-InducedNeurotoxicity
Generally,braininjuryinanyformtriggerstheaccumulation
of substances (neurotransmitters, ions, ﬂuid, etc.) that areJournal of Toxicology 9
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initiallyproducedtocompensateorrepairthedamage.How-
ever, uncontrolled accumulation of these substanceswill lead
to neurotoxicity in the CNS. Injury to the brain could be
caused by endogenous factors such as ischemia due to embo-
lism/thromboembolism of an artery or tumour growth that
results in anoxia and glucose deﬁciency to the neurons and
othercellsinthebrain.Physicalinjurytothebraincouldalso
cause trauma that confers neurotoxicity.
6.1. Cerebral Ischemia. Cerebral ischemia is an event that
leads to neurotoxicity during the onset of ischemia as well as
during reperfusion. Temporal regulation of miRNA expres-
sion has been shown in the brain of rat models subjected to
middle cerebral artery occlusion (MCAo) [140]. In addition,
biphasic expression of miRNAs has also been demonstrated
inthesameanimalmodels.Thetemporalandbiphasicregul-
ation of these miRNAs have been proposed to play a crucial
roleeitherintheacuteinjuryphaseorthelaterecoveryphase
[141]. An upregulation of the antiapoptotic miR-21 has been
shown to protect neurons from death in cerebral ischemic
model. MiR-21 was demonstrated to target FASLG, a mem-
ber of the tumour necrosis factor-α family and cell death
inducing ligand [142]. In an in vitro model of cerebral10 Journal of Toxicology
ischemia, increase of miR-497 expression following oxygen-
glucose deprivation, correlated with increased cell death and
downregulation of its antiapoptotic proteins, Bcl2 and Bclw
[143].
A vital new discovery of neurotoxicity is the contribution
of postinjury edema that results in accumulation of water.
Transport of water in and out of brain cells are controlled by
aquaporins that are located at the cell membrane. The edema
formation induces death of neurons, and hence neurotoxi-
city, which can be countered by controlling edema forma-
tion. AQP4 and AQP1 are expressed predominantly in astro-
cytesandiscrucialinﬂuidclearanceincerebraledema[144].
Sepramaniam et al. [145] investigated changes in aquaporin
1 and 4 expression in the MCAo rat brain and identiﬁed
miR-320a as a potential negative modulator of AQP1 and
AQP4. Anti-miR-320a could reduce infarct volume in cere-
bral ischemia with concurrent elevation in AQP1 and AQP4
mRNA and protein expression. Inhibition of miR-320a sub-
sequently reduced the infarct volume and improved the neu-
rological functions of the rat models. Similarly, downregu-
lation of miR-320 was also observed in peripheral blood of
stroke patient who showed good recovery and good clinical
outcome (modiﬁed Rankin Scale, mRS ≤ 2) as compared to
patients with poor clinical outcome (mRS > 2) [146].
6.2. Traumatic Brain Injury. Altered expression of miRNAs
in the cortex and hippocampus was also observed in trau-
matic brain injury models [147]. Diﬀerential regulation of
severalmiRNAs(miR-107,miR-130a,miR-223,miR-292-5p,
miR-433-3p, miR-451, miR-541, and miR-711) was observed
with controlled cortical impact injury [148]. These miRNAs
were predicted to regulate the cellular processes that com-
prised diﬀerentiation, proliferation, signal transduction, and
transcriptional regulation [148]. It is noteworthy that miR-
107thatwasdownregulated in traumaticbraininjuryinvers-
ely regulated progranulin which was involved in wound re-
pair or healing [149, 150]. Thus, in brain injury or during
ischemia, the consequences of neurotoxicity are compensat-
ed (remedial activities) almost immediately and are controll-
ed by the riboregulators (miRNA) as the ﬁrst level of reg-
ulation.
7. Conclusion
MiRNAs have been found to be highly dysregulated in dif-
ferent stages of neurotoxicity. Neurotoxicity ranges from the
impact of drugs to neurodegeneration in cells of the nervous
system. These processes have been found to result in changes
in expression of speciﬁc miRNAs. Hence such miRNAs could
be exploited as potential biomarkers for diagnostic or pro-
gnostic purposes. Moreover some of these miRNAs can be
developed as therapeutic agents or targets to prevent neuro-
toxicity.
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